18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications

Area of Science:

• Nuclear Medicine
• Oncology
• Radiochemistry

Background:

• Estrogen receptor (ER) expression in breast cancer is crucial for prognosis and response to endocrine therapy.
• Traditional ER assessment relies on invasive in vitro assays of tumor biopsies.
• In vivo evaluation of ER expression is now possible with advancements in PET imaging.

Purpose of the Study:

• To review the biology and pharmacokinetics of (18)F-FES.
• To highlight current clinical experiences with (18)F-FES PET in breast cancer and other diseases.
• To discuss the potential clinical applications and future use of (18)F-FES PET.

Main Methods:

• Review of existing literature on (18)F-FES PET imaging.
• Analysis of clinical studies involving (18)F-FES PET in various diseases.
• Discussion of the biological and pharmacokinetic properties of (18)F-FES.

Main Results:

• (18)F-FES PET can quantify in vivo ER expression.
• (18)F-FES PET has shown potential as a predictive assay for treatment response.
• (18)F-FES PET can assess in vivo pharmacodynamic response to endocrine therapy.

Conclusions:

• (18)F-FES PET is a valuable tool for assessing ER status non-invasively.
• This imaging modality holds promise for personalized medicine in breast cancer treatment.
• Further clinical application and validation of (18)F-FES PET are anticipated.